334009-77-7Relevant academic research and scientific papers
Regio-selective reduction of the C-C double bonds in α,β- unsaturated acyl 4-substituted oxazolidin-2-ones and oxazolidine-2-thiones
Li, Shao-Gang,Jin, Jian-Wei,Wu, Yikang
experimental part, p. 846 - 850 (2012/02/02)
Selective saturation of the conjugated C-C double bonds in the title compounds was examined in a systematic way for the first time. Many established protocols effective for similar reduction of α,β-unsaturated ketones and esters in the literature were found to be inapplicable in the present context. The most satisfactory results were finally obtained using the DIBAL-H/MeLi/CuI/HMPA/THF conditions.
Nonpeptide αvβ3 antagonists. Part 2: Constrained glycyl amides derived from the RGD tripeptide
Meissner, Robert S.,Perkins, James J.,Duong, Le T.,Hartman, George D.,Hoffman, William F.,Huff, Joel R.,Ihle, Nathan C.,Leu, Chih-Tai,Nagy, Rose M.,Naylor-Olsen, Adel,Rodan, Gideon A.,Rodan, Sevgi B.,Whitman, David B.,Wesolowski, Gregg A.,Duggan, Mark E.
, p. 25 - 29 (2007/10/03)
Mimetics of the RGD tripeptide are described that are potent, selective antagonists of the integrin receptor, αvβ3. The use of the 5,6,7,8-tetrahydro[1,8]naphthyridine group as a potency-enhancing N-terminus is demonstrated. Two 3-substituted-3-amino-propionic acids previously contained in αIIbβ3 antagonists were utilized to enhance binding affinity and functional activity for the targeted receptor. Further affinity increases were then achieved through the use of cyclic glycyl amide bond constraints.
Integrin receptor antagonists
-
, (2008/06/13)
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 an
